Advertisement Β· 728 Γ— 90
#
Hashtag
#tcsc
Advertisement Β· 728 Γ— 90

Between 50-75% of patients with Stage 4 colorectal cancer spread to the liver are now living past the five-year mark with the right combination of surgery, chemo and immunotherapy. Hope is real. #TCSC #ColorectalCancer #CancerHope #MetastaticCancer #SurvivalRates

0 0 0 0
Preview
When stage 4 colon cancer spread to her liver, Peggy was given months to live. That was 13 years ago. Coordinated surgery, chemo and immunotherapy are improving survival for patients with stage 4 colon cancer that has spread to the liver.

Given just six weeks to live after a Stage 4 colon cancer diagnosis, Peggy Martin is now celebrating 13 years of survival. A clinical trial and coordinated care made all the difference. www.uchealth.org/today/stage-... #TCSC #ColonCancer #CancerSurvivor #ClinicalTrials #HopeForCancer #Stage4

1 0 1 0

Self-advocacy is one of the most powerful tools a cancer patient has. Ask questions. Seek second opinions. Trust your instincts. You know your body best. #TCSC #CancerCommunity #YouAreNotAlone #SurvivorStrong #MentalHealthMatters

0 0 0 0
Preview
Redefining Strength During Cancer and Chronic Illness | CURE Amanda shares advice on resilience, self-advocacy and finding strength while navigating cancer survivorship and chronic GVHD.

Amanda’s story of navigating cancer survivorship and chronic GVHD is a powerful reminder that strength does not always look the way we expect. Resilience, self-advocacy and community matter. www.curetoday.com/view/redefin... #TCSC #CancerSurvivor #CancerStrong #GVHD #PatientAdvocacy #Resilience

0 0 1 0

uPAR shows up on the most dangerous cancer cells AND the support cells that protect tumors. Targeting both at once could be the breakthrough solid tumor patients have been waiting for. #TCSC #CancerScience #Immunotherapy #CancerBreakthrough

0 0 0 0
Preview
uPAR-targeted CAR T cells shrank solid tumors and cleared metastases in mice Chimeric antigen receptor T-cell therapyβ€”CAR T for shortβ€”has been a major advance in treating blood cancers like leukemia and lymphoma. But the immunotherapy has struggled against solid tumors for two...

BREAKING: Scientists at Memorial Sloan Kettering have identified a protein called uPAR that could unlock CAR T cell therapy for solid tumours; lung, pancreatic, ovarian and more. Game-changing research. medicalxpress.com/news/2026-03... #TCSC #CancerResearch #CART #SolidTumors #Oncology

0 0 1 0

Mrinali Dhembla had Lynch syndrome; a genetic mutation that made her cancer highly vulnerable to immunotherapy. Knowing your genetic risk can save your life. Get tested. #TCSC #LynchSyndrome #CancerPrevention #KnowYourRisk

0 0 0 0
Preview
26-year-old now 'cancer-free' thanks to new colorectal cancer treatment A 26-year-old is now "cancer-free" after receiving a new treatment for colorectal cancer.

A 26-year-old beat Stage 3 rectal cancer in just 4 months using dual immunotherapy; no chemo, no surgery. This is precision medicine doing the impossible. Read her incredible story. abcnews.go.com/GMA/Wellness... #TCSC #CancerFree #ColorectalCancer #Immunotherapy

0 0 1 0

Combining treatments is where oncology is heading. Smarter strategies, better outcomes, longer lives. #TCSC

0 0 0 0
Preview
New treatment reduces recurrence and improves survival in bladder cancer A combination of immunotherapy and targeted cancer treatment given before and after surgery may reduce the risk of recurrence and improve survival in patients with muscle‑invasive bladder cancer who cannot tolerate conventional chemotherapy. The findings come from a new study from Karolinska Institutet, published in The New England Journal of Medicine.

A new bladder cancer approach combining immunotherapy with targeted treatment shows reduced recurrence and improved survival. A promising step forward.
#BladderCancer #Immunotherapy #CancerResearch #TCSC
news.ki.se/new-treatmen...

0 0 1 0

Smarter treatment decisions mean fewer side effects and better outcomes. Personalised care is no longer optional, it’s essential. #TCSC

0 0 0 0
Preview
Male Breast Cancer Tool Predicts Chemotherapy Benefit New risk stratification may help identify men with luminal early breast cancer who could omit chemotherapy. Read more.

A new tool for male breast cancer patients helps predict who will truly benefit from chemotherapy, reducing unnecessary treatment and improving personalised care.
#PrecisionMedicine #BreastCancer #Oncology #TCSC
www.emjreviews.com/oncology/new...

0 0 0 0

Breakthroughs like this don’t just improve science, they improve survival. Scaling treatment access matters as much as discovering it. #TCSC

1 0 0 0
Preview
Scientists Break 50-Year-Old Bottleneck To Supercharge Cancer Drug Production A long-standing challenge in cancer drug manufacturing may be shifting.

A 50-year bottleneck in cancer drug production has finally been broken, potentially boosting access to life-saving treatments like doxorubicin. Faster production could mean faster care.
#CancerResearch #Innovation #Oncology #TCSC
scitechdaily.com/scientists-b...

0 0 2 0

The right treatment for the right patient at the right time. That’s the future of cancer care. #TCSC

0 0 0 0
Preview
FDA Approves PD-L1 Test to Guide Keytruda Use in Esophageal and GEJ Cancer | CURE FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda.

A newly approved PD-L1 test is helping guide Keytruda use in esophageal and GEJ cancers, matching patients with treatments more precisely than ever before.
#PrecisionMedicine #CancerTreatment #TCSC
www.curetoday.com/view/fda-app...

0 0 1 0

Hope should always be grounded in science. Patients deserve treatments that are proven to work. #TCSC

0 0 0 0
Preview
From Farm to Pharmacy: Controversial Antiparasitics in Cancer Care | Pharmacy Times Ivermectin, fenbendazole, and mebendazole have gained traction as alternative cancer therapies despite a lack of clinical evidence.

Not every β€œalternative” cancer treatment is backed by science. Experts are urging caution around antiparasitic drugs being promoted without clinical evidence. Evidence still matters.
#CancerAwareness #EvidenceBased #TCSC
www.pharmacytimes.com/view/from-fa...

0 0 1 0

Progress isn’t just about stronger treatments. It’s about making them safer and more tolerable for patients. #TCSC

0 0 0 0
Preview
Balancing Immunotherapy Benefits and Risks in Cancer Care | CURE Dr. Brittany Dulmage discusses how management of immune-related side effects can help patients stay on immunotherapy without compromising its effectiveness.

Immunotherapy is transforming cancer care, but managing side effects is just as critical as the breakthrough itself. Smarter care means better outcomes and safer treatment journeys.
#Immunotherapy #CancerCare #TCSC
www.curetoday.com/view/balanci...

0 0 1 0

Stories like this remind us what progress really looks like. Behind every breakthrough is a life changed. #Survivorship #TCSC

0 0 0 0
Preview
Thriving after a rectal cancer diagnosis Kyle Kipke was diagnosed with rectal cancer and received chemotherapy and radiation as treatment at Michigan Medicine.

A powerful survival story: thriving after a rectal cancer diagnosis. With the right treatment and resilience, patients are not just surviving, they’re rebuilding their lives. #CancerSurvivor #Hope #TCSC
www.michiganmedicine.org/health-lab/t...

0 0 1 0

When time matters, speed and accuracy save lives. AI is starting to deliver both. #TCSC

0 0 0 0
Preview
Tapping AI for precision-guided cancer therapies - @theU New β€˜lab-on-a-chip’ platform may enable same-day treatment decision for pediatric cancer patients.

AI is now helping guide cancer treatment decisions in real time. A new lab-on-a-chip platform could allow same-day therapy choices for pediatric patients. Faster decisions, better outcomes.
#AIinHealthcare #PrecisionMedicine #TCSC
attheu.utah.edu/facultystaff...

0 0 1 0

Minimising damage while maximising impact is where modern cancer treatment is heading. This is a solid step in that direction. #TCSC

0 0 0 0
Preview
Cryoablation System Delivers Positive Topline Results in Kidney Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Use of the ProSense Cryoablation System in patients with kidney cancer resulted in an 83.9% recurrence-free rate among 112 patients in the ICESECRET clinical trial (NCT02399124).

New results from a kidney cancer trial show cryoablation technology delivering promising outcomes for small tumours. Less invasive, more targeted, and increasingly effective.
#KidneyCancer #CancerInnovation #TCSC
www.targetedonc.com/view/cryoabl...

0 0 1 0

Survival is the goal. Living well afterwards is the mission. Research like this is finally treating both as equally important. #TCSC

0 0 0 0
Preview
MUSC The Medical University of South Carolina aims to empower the state and beyond through innovative research, education, and commitment to patient care. MUSC is home to six colleges, 16 hospitals, a grow...

Life after cancer treatment matters just as much as survival. The BRIGHT trial is focusing on improving quality of life for head and neck cancer patients, where recovery can be especially challenging.
#CancerSurvivorship #QualityOfLife #TCSC
web.musc.edu/about/news-c...

1 0 1 0

Cancer treatment is no longer one-size-fits-all. The more personalised it becomes, the better the results. #TCSC

0 0 0 0
Preview
Roswell Park First in Region to Offer New Treatment for Tumors Adaptive radiation therapy reduces the risk of side effects due to excessive radiation

A major step forward in precision care: adaptive radiation therapy is now being offered, tailoring treatment in real time to improve outcomes and reduce unnecessary exposure. This is how treatment gets smarter.
#RadiationTherapy #CancerCare #TCSC
www.roswellpark.org/newsroom/202...

0 0 1 0